Is UK Medical Cannabis Creating a Two-Tier Healthcare System?

The landscape of medical cannabis in the UK has shifted significantly since 2018, yet a contentious debate continues: is access to this treatment now creating a two-tier healthcare system where NHS funding and legal prescribing rules leave many patients stuck between private clinics and limited NHS support?

Understanding the 2018 Rescheduling: What Changed?

Before November 2018, cannabis-based products for medicinal use (CBPMs) were virtually off the table for medical professionals in the UK. The Misuse of Drugs Act had classed cannabis as a Schedule 1 substance, indicating https://vergemagazine.co.uk/can-you-get-medical-cannabis-on-the-nhs-a-guide-to-the-uk-system/ 'no recognised medicinal value.' This meant cannabis-derived medicines could not be prescribed legally under the NHS at all.

The rescheduling in November 2018 to Schedule 2 reclassified cannabis-based medicines as controlled substances with recognised medical use. This change theoretically allowed specialist doctors to prescribe CBPMs legally on the NHS under strict controls. It was a big policy step that many hoped would open the doors to patient access.

What Schedule 2 Means in Practice

• CBPMs can be prescribed by specialist physicians only—general practitioners (GPs) remain unable to do so.
• The medicines must be manufactured to pharmaceutical standards and meet strict regulatory oversight.
• Prescriptions can be dispensed through community pharmacies like other controlled drugs, but often with added paperwork for storage and record-keeping.

The 2018 rescheduling didn’t deliver widespread access, but it did establish a legal framework where prescribing medical cannabis is possible—setting it apart from illegal or unlicensed cannabis products.

NHS Funding vs Legal Prescribing: Where’s the Gap?

Legal prescribing does not always mean NHS funding. This distinction is at the heart of many patients' frustrations and the emergence of what looks increasingly like a two-tier healthcare system.

What NHS Funding Means for Medical Cannabis

The National Institute for Health and Care Excellence (NICE) is responsible for appraising new medicines and treatments to determine whether they should be routinely funded on the NHS. To date, NICE has not recommended routine NHS funding for most cannabis-based medicines except in very limited circumstances.

As a result, even when specialist consultants prescribe medical cannabis legally, NHS patients often face a postcode lottery: some hospital trusts or local NHS clinical commissioning groups (CCGs) may agree to fund treatment in exceptional cases, while others do not. Often, funding is restricted to specific indications such as rare epilepsy syndromes where robust evidence exists.

What Happens When NHS Funding Is Refused?

Patients who do not meet the strict NHS funding criteria but want medical cannabis legally prescribed find themselves looking elsewhere—usually private medical cannabis clinics.

These clinics operate outside the NHS and charge patients directly for consultations and prescribing. The medicine itself can also be costly without NHS subsidies. This has led to widespread concern that access to medical cannabis depends on patients’ ability to pay upfront private fees, rather than clinical need alone.

Specialist Only Prescribing: A Necessary Gatekeeper or Barrier?

Under UK law, only specialist consultants can prescribe cannabis-based medicines legally. GPs cannot initiate these prescriptions, though some may continue them under shared care agreements.

This specialist-only rule is intended to ensure that prescribing is clinically appropriate and that only patients who genuinely might benefit receive these complex medicines. However, the lack of specialist consultants comfortable or willing to prescribe CBPMs adds another hurdle.

• Specialist clinics offering medical cannabis may be few and far between, increasing wait times and travel burdens for patients.
• Some consultants remain cautious or sceptical about medical cannabis due to limited long-term data or the absence of NICE guidance.
• This limits patients' ability to access NHS prescriptions, pushing more towards private clinics.

The specialist-only prescribing rule, although rooted in clinical governance, can look like a systemic barrier to access, especially when combined with inconsistent NHS funding.

Unlicensed Cannabis-Based Medicines and NHS Caution

Many cannabis products offered in private clinics are unlicensed medicines—meaning they have not gone through the full regulatory approval process by the Medicines and Healthcare products Regulatory Agency (MHRA). While legal to prescribe off-label by specialist doctors, the NHS is generally cautious about endorsing or funding unlicensed treatments due to:

• Uncertainty about consistent dosing and product composition.
• Risks related to quality, safety, and efficacy.
• The lack of large-scale clinical trials required for standard licensing.

This cautious stance leaves patients caught between strict NHS pathways and a private market offering many unlicensed options at a cost.

For those navigating this complex landscape, tools like medicalcannabis.co.uk offer searchable directories and clinic comparisons, while educational resources such as releaf.co.uk help patients understand how medical cannabis might fit into their care.

Does This Create a Two-Tier Healthcare System?

In many ways, yes. The combination of legal—but specialist-limited—prescribing, tightly controlled NHS funding, and the proliferation of private clinics offering costly consultations and medicines means access is increasingly divided by ability to pay.

Feature NHS Medical Cannabis Access Private Medical Cannabis Clinics Prescribing Authority Specialist consultants only Specialist consultants, often those working within private clinics Funding Usually NHS-funded only in very specific, rare cases Patients pay upfront for consultation and medicines Cost to Patient Minimal or none if funded (rare) Private fees for clinic visits + medicine costs (varies, often substantial) Availability Limited; depends on local NHS policies and willingness of specialists More widely available but less regulated

Many patients who cannot wait or do not qualify for NHS funding feel compelled to seek private care. This effectively creates a healthcare landscape where two tiers coexist: one governed by NHS rules and funding constraints, and the other accessible primarily to those who can afford private costs.

Conclusion: What Needs to Change?

The UK has made important legal strides since 2018 towards recognising medical cannabis as a legitimate treatment option, but the gap between legal prescribing and practical access remains wide.

For a genuinely equitable healthcare system, these issues need addressing:

1. Clearer NHS funding pathways: More robust NICE guidance and expanded NHS funding could reduce postcode lottery effects and ensure patients receive treatments based on clinical need, not income.
2. Enhanced specialist education and capacity: More specialists trained and comfortable prescribing cannabis-based medicines would ease bottlenecks.
3. Greater transparency on private clinic pricing and treatment outcomes: To avoid exploitative costs and help patients make informed choices.
4. Ongoing research into quality and efficacy: To move unlicensed CBPMs towards licensed approval and wider NHS acceptance.

Until then, the UK’s medical cannabis system risks perpetuating disparities—where lawful access is not enough, but affordability and knowledge gaps define who can get treatment.

For patients wondering about their options, reputable sites like medicalcannabis.co.uk can guide you to clinics, while releaf.co.uk offers helpful plain-English information to better understand the legal and funding realities of UK medical cannabis.